ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
| Autor: | Nuhad K. Ibrahim, Mary Tagliaferri, Andrew D. Seidman, Javier Cortes, Sara M. Tolaney, Chris Twelves, Alison L. Hannah, Véronique Diéras, Carey K. Anders, Hope S. Rugo, Volkmar Müller, Debu Tripathy |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_treatment chemotherapy Polyethylene Glycols 0302 clinical medicine Heterocyclic Compounds brain metastases Clinical endpoint etirinotecan pegol Neoplasm Metastasis Cancer Brain Neoplasms General Medicine Middle Aged Metastatic breast cancer Progression-Free Survival Local 030220 oncology & carcinogenesis 6.1 Pharmaceuticals Female metastatic breast cancer medicine.drug Adult medicine.medical_specialty Anthracycline NKTR-102 Clinical Trials and Supportive Activities Oncology and Carcinogenesis Breast Neoplasms Heterocyclic Compounds 4 or More Rings Capecitabine 03 medical and health sciences Breast cancer Clinical Research Internal medicine Breast Cancer medicine Humans Oncology & Carcinogenesis Aged Chemotherapy Taxane business.industry Neurosciences Evaluation of treatments and therapeutic interventions 4 or More Rings medicine.disease 030104 developmental biology Neoplasm Recurrence Neoplasm Recurrence Local Topoisomerase I Inhibitors business |
| Zdroj: | Future oncology (London, England), vol 15, iss 19 |
| Popis: | The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from the Phase III BEACON trial, this ongoing randomized, Phase III trial compares etirinotecan pegol to drugs commonly used for advanced breast cancer in patients with stable, treated breast cancer brain metastases who have been previously treated with an anthracycline, taxane and capecitabine. The primary end point is overall survival. Secondary end points include objective response rate, progression-free survival and time to CNS disease progression or recurrence in patients with/without CNS lesions present at study entry. Trial registration number: NCT02915744. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|